{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:21:23Z","timestamp":1787318483491,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Johan Perssons stiftelse"},{"name":"Blodsjukas f\u00f6rening i S\u00f6dra regionen; www.blodcancerforbundet.se\/sodra"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The aim of the study was to assess the role of allogeneic stem cell transplantation (SCT) in patients diagnosed with\n                    <jats:italic>BCR\u2010ABL1<\/jats:italic>\n                    \u2010positive acute myeloid leukemia (AML). Fifty\u2010seven patients (median age, 48 years, range: 19\u201067) with\n                    <jats:italic>BCR\u2010ABL1<\/jats:italic>\n                    positive AML undergoing SCT were identified. The majority of the patients (70%) received a TKI before the transplant. At SCT 48 patients were in CR (45 in CR1), while 9 patients were transplanted in a more advanced stage of the disease. MRD was negative (\n                    <jats:italic>BCR\u2010ABL1\/ABL<\/jats:italic>\n                    \u2009&lt;\u200910\n                    <jats:sup>4<\/jats:sup>\n                    ) at time of SCT in 36.1% (14\/40). After SCT, 16 (61.5%) out of 26 patients with MRD positive at transplantation reached MRD negativity. After a median follow\u2010up of 6.3 years (0.7\u201314.2), NRM, RI, LFS, OS, and GRFS at 5 years were 18.1%, 37%, 44.2%, 53.8%, and 32.1%, respectively. The cumulative incidence of acute GvHD grade II\u2010IV was 16.4%, incidence of chronic GvHD 24.9%, and of extensive cGvHD 21.4%, respectively. In patients who received SCT in CR1, 5\u2010yr NRM, RI, LFS, OS, and GRFS were 15.9%, 36.4%, 46.5%, 59.4%, and 34.9%, respectively. Univariate analysis showed that age (&lt;50 vs. \u226550 years) was associated with RI (5\u2010yr: 22.7 vs. 50%), LFS (5\u2010yr: 61.9 vs. 31.8%), and GRFS (5\u2010yr: 52.4 vs. 18.2%), whereas MRD\u2010negative status before SCT was associated with an improved GRFS (38.9 vs. 16.7%). We conclude that the outcome of patients &lt;50 years of age with\n                    <jats:italic>BCR\u2010ABL1\u2010<\/jats:italic>\n                    positive AML receiving allogeneic SCT in CR is relatively favorable, possibly reflecting the beneficial effect of the use of TKI.\n                  <\/jats:p>","DOI":"10.1002\/ajh.24928","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T04:36:37Z","timestamp":1507005397000},"page":"31-39","source":"Crossref","is-referenced-by-count":22,"title":["Relatively favorable outcome after allogeneic stem cell transplantation for\n                    <i>BCR\u2010ABL1<\/i>\n                    \u2010positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-4423","authenticated-orcid":false,"given":"Vladimir Lj","family":"Lazarevic","sequence":"first","affiliation":[{"name":"Sk\u00e5ne University Hospital, Department of Hematology, Oncology and Radiation Physics Stem Cell Centre, Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Antoine, ALWP office, Service d'H\u00e9matologie et de Th\u00e9rapie cellulaire Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Depei","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Soochow University, Department of Hematology Suzhou Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub\u2010Agha","sequence":"additional","affiliation":[{"name":"CHU de Lille, LIRIC, Universit\u00e9 Lille  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer Toulouse, Oncopole Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapy and Allogeneic Stem Cell Transplantation Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas","family":"Schaap","sequence":"additional","affiliation":[{"name":"Department of Hematology Radboud University Nijmegen Medical Centre Nijmegen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC Cancer Institute, University Medical Center Rotterdam Rotterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Maillard","sequence":"additional","affiliation":[{"name":"Hopital La Miletrie, Head of the Bone Marrow Transplant Unit, Clinical Hematology Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Pioltelli","sequence":"additional","affiliation":[{"name":"Ospedale San Gerardo, Clinica Ematologica dell`Universita Milano\u2010Biocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde\u2010Dahl","sequence":"additional","affiliation":[{"name":"Department of Hematology Clinic for Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Lenhoff","sequence":"additional","affiliation":[{"name":"Sk\u00e5ne University Hospital, Department of Hematology, Oncology and Radiation Physics Stem Cell Centre, Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Houhou","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Antoine, ALWP office, Service d'H\u00e9matologie et de Th\u00e9rapie cellulaire Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic, IDIBAPS Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Antoine, ALWP office, Service d'H\u00e9matologie et de Th\u00e9rapie cellulaire Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Antoine, ALWP office, Service d'H\u00e9matologie et de Th\u00e9rapie cellulaire Paris France"},{"name":"Department of Bone Marrow Transplantation Chaim Sheba Medical Center, Tel\u2010 Hashomer and Tel\u2010Aviv University, Tel Aviv, Israel; Chairman, Acute Leukemia Working Party of the EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"2391","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","journal-title":"Blood. 2016"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1309\/B4NVER1AJJ84CTUU"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.701739"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12301"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2014.09.002"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2721-z"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20578"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000334109"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0092"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00890.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.01.012"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2855-z"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2004.00175.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.206"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-609032"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14260"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12841"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","author":"Hourigan CS","year":"2017","journal-title":"Leukemia."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.307"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30130"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707562"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08472.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1182\/blood.V124.21.4516.4516","article-title":"CML patients with resistance to tyrosine kinase inhibitors and without BCR\u2010ABL1 resistance mutation frequently carry other gene mutations","volume":"124","author":"Schnittger S","year":"2014","journal-title":"Blood."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.10"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T03:14:08Z","timestamp":1695525248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/ajh.24928"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24928","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,31]]}}}